Antibiotic Prescription, Complications, Healing, Hospital Discharge, Infection Due to Resistant Bacteria, Intensive Care Unit, Multi-antibiotic Resistance, Outcome, Fatal, Risk Factors
Conditions
Brief summary
This study is observational, multicenter and prospective study for surveillance of the use of new antibiotics in pediatrics for treated pediatrics infections due to multi-resistant bacteria
Detailed description
The main of this study is to evaluate the relevance of prescribing "new antibiotics" according to the antibiogram of the isolated bacteria or in the absence of bacteriological documentation As this is a surveillance study, the clinical and biological characteristics of the children included will be described.
Interventions
None listed
Sponsors
Association Clinique Thérapeutique Infantile du val de Marne
Pfizer
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
* Children under 18 years of age * Hospitalized in France in a hospital center working with the ACTIV/GPIP network * Treated with one or more of the following antibiotics: * Colimycin (Colistimethate sodium) * Cefiderocol * Aztreonam in combination * Ceftolozane-Tazobactam * Ceftazidime-avibactam * Meropenem/vaborbactam * Imipenem/Relebactam * Tigecycline * Daptomycin * Ceftaroline fosamil * Tedizolid phosphate * Fidaxomicin * Ceftobiprole * Dalbavancin In association with a documented infection performed by: * Blood culture * Normally sterile site * Cerebrospinal fluid * Pleural fluid * Pleura * Peritoneum * Joint fluid * Other * Urine sampling if the bacteria was considered responsible for the infection (associated with a leukocyturia ≥10,0000) * Respiratory specimens if the bacteria was considered responsible for the infection * Sampling on material such as:Intubation probe, Orthopedic, Urological, Central Nervous System (CNS),.... * Related to colonization with multidrug-resistant bacteria without documentation.
Exclusion criteria
* Refusal of participation by the patient or his/her parent * Medical history of mucoviscidosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relevance of prescribing "new antibiotics" according to patient status | 1 year | Type of new antibiotics prescribed for pediatrics infections caused by multi-resistant bacteria according to the antibiogram of the isolated bacteria or in the absence of bacteriological documentation |
| Relevance of prescribing "new antibiotics" | 1 year | how are used new antibiotics prescribed for pediatrics infections caused by multi-resistant bacteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Describe Bacterial epidemiology of infections associated with prescription of new antibiotics | 1 year | Characteristic of bacteria associated with prescription of new antibiotics |
| Identify Risks factors for multi-resistant bacteria | 1 year | Type of conditions responsible of multi-resistant such as comorbidities, travel, previous hospitalization, previous antibiotherapy, |
| Describe Context of drug Prescription | 1 year | How antibiotics medical prescriptions are controlled and validated |
| Department involved in medical prescribing | 1 year | Number of department involved in medical prescriptions |
| Describe Associated Antibiotherapies type | 1 year | Type of drug association prescribed |
| Describe Associated Antibiotherapies | 1 year | Number of drug association prescribed |
| Describe patients outcome | 1 year | Proportion of patients clinically and bacteriologically recovered |
Countries
France
Contacts
STUDY_DIRECTORLevy Corinne
Association Clinique Thérapeutique Infantile du val de Marne
PRINCIPAL_INVESTIGATORCohen Robert
Association Clinique Thérapeutique Infantile du val de Marne
Outcome results
None listed